These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36628904)

  • 1. Quality of life after treatment with immune checkpoint inhibitors for lung cancer; the impact of age.
    Suazo-Zepeda E; Vinke PC; Heuvelmans MA; Sidorenkov G; Hiltermann TJN; de Bock GH
    Lung Cancer; 2023 Feb; 176():89-97. PubMed ID: 36628904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life and its influencing factors among lung cancer patients receiving immune checkpoint inhibitors: A cross-sectional study.
    Wang H; Dong Y; Fan T; Zhu S; Zhou Y; Song Y; Pan S; Wu Q; Li Y; Han Y
    Eur J Oncol Nurs; 2024 Feb; 68():102507. PubMed ID: 38219475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study.
    Cotté FE; Voillot P; Bennett B; Falissard B; Tzourio C; Foulquié P; Gaudin AF; Lemasson H; Grumberg V; McDonald L; Faviez C; Schück S
    J Med Internet Res; 2020 Sep; 22(9):e19694. PubMed ID: 32915159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study.
    de Mol M; Visser S; Aerts J; Lodder P; van Walree N; Belderbos H; den Oudsten B
    BMC Cancer; 2020 May; 20(1):431. PubMed ID: 32423432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
    Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
    Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review.
    Hall ET; Singhal S; Dickerson J; Gabster B; Wong HN; Aslakson RA; Schapira L;
    J Pain Symptom Manage; 2019 Jul; 58(1):137-156.e1. PubMed ID: 30905677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
    O'Reilly A; Hughes P; Mann J; Lai Z; Teh JJ; Mclean E; Edmonds K; Lingard K; Chauhan D; Lynch J; Au L; Ludlow A; Pattison N; Wiseman T; Turajlic S; Gore M; Larkin J; Husson O
    Support Care Cancer; 2020 Feb; 28(2):561-570. PubMed ID: 31089820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).
    Van der Weijst L; Aguado-Barrera ME; Azria D; Berkovic P; Boisselier P; Briers E; Bultijnck R; Calvo-Crespo P; Chang-Claude J; Choudhury A; Defraene G; Demontois S; Dunning AM; Elliott RM; Ennis D; Faivre-Finn C; Franceschini M; Gutiérrez-Enríquez S; Herskind C; Higginson DS; Kerns SL; Johnson K; Mollà M; Lambrecht M; Ramos M; Rancati T; Rimner A; Rosenstein BS; De Ruysscher D; Salem A; Sangalli C; Seibold P; Sosa-Fajardo P; Sperk E; Stobart H; Summersgill H; Surmont V; Symonds P; Taboada-Lorenzo B; Talbot CJ; Valdagni R; Vega A; Veldeman L; Veldwijk MR; Ward T; Webb A; West CML; ; Lievens Y
    Lung Cancer; 2022 Apr; 166():228-241. PubMed ID: 35334417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer.
    Marschner N; Zacharias S; Lordick F; Hegewisch-Becker S; Martens U; Welt A; Hagen V; Gleiber W; Bohnet S; Kruggel L; Dille S; Nusch A; Dörfel S; Decker T; Jänicke M
    JAMA Netw Open; 2020 Mar; 3(3):e200643. PubMed ID: 32154886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
    Korde R; Veluswamy R; Allaire JC; Barnes G
    Curr Med Res Opin; 2022 Aug; 38(8):1361-1368. PubMed ID: 35575164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes and experiences from a prospective cohort study of older patients with cancer on checkpoint inhibitors: The ELDERS study.
    Gomes F; Khatoon B; Sawyer C; Punnett G; Farrington N; Yorke J
    J Geriatr Oncol; 2024 Jun; 15(5):101777. PubMed ID: 38704912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
    Schulz TU; Zierold S; Sachse MM; Pesch G; Tomsitz D; Schilbach K; Kähler KC; French LE; Heinzerling L
    Eur J Cancer; 2022 Nov; 176():88-99. PubMed ID: 36198246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frailty is associated with decline in health-related quality of life of patients treated for head and neck cancer.
    de Vries J; Bras L; Sidorenkov G; Festen S; Steenbakkers RJHM; Langendijk JA; Witjes MJH; van der Laan BFAM; de Bock GH; Halmos GB
    Oral Oncol; 2020 Dec; 111():105020. PubMed ID: 33045628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between age and patient-reported outcomes, emergency department visits, and hospitalizations among lung cancer patients receiving immune checkpoint inhibitors.
    Fleszar-Pavlovic SE; Natori A; Moreno PI; Medina HN; Sookdeo V; MacIntyre J; Penedo FJ
    Psychooncology; 2024 Jan; 33(1):e6293. PubMed ID: 38282219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients.
    Quinten C; Coens C; Ghislain I; Zikos E; Sprangers MA; Ringash J; Martinelli F; Ediebah DE; Maringwa J; Reeve BB; Greimel E; King MT; Bjordal K; Flechtner HH; Schmucker-Von Koch J; Taphoorn MJ; Weis J; Wildiers H; Velikova G; Bottomley A; ;
    Eur J Cancer; 2015 Dec; 51(18):2808-19. PubMed ID: 26602015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
    Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
    Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
    Adenis A; Kulkarni AS; Girotto GC; de la Fouchardiere C; Senellart H; van Laarhoven HWM; Mansoor W; Al-Rajabi R; Norquist J; Amonkar M; Suryawanshi S; Bhagia P; Metges JP
    J Clin Oncol; 2022 Feb; 40(4):382-391. PubMed ID: 34730989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
    Zhang L; Bai L; Liu X; Liu Y; Li S; Liu J; Zhang S; Yang C; Ren X; Cheng Y
    Thorac Cancer; 2020 May; 11(5):1170-1179. PubMed ID: 32134200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
    Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.